Cystic Fibrosis Genetherapy Development Option Excercise

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic FibrosisBoehringer Ingelheim has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology   Partners aim to expedite the development of the novel, inhaled cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy BI 3720931 as a long-lasting therapeutic option for patients with cystic fibrosis (CF)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news